VERA

Vera is a clinical-stage pharma with no product revenue in any year (FY2021–FY2025 all blank), so there is nothing to value on fundamentals — only pipeline optionality. At $43.15 on 64.2M shares the equity is worth ~$2.8B, of which just $355M is cash; the rest is the market pricing the lead program (atacicept-class candidate for IgA nephropathy and related indications). With zero revenue and a $4.66 diluted loss, P/E and P/S are meaningless, and the entire thesis rests on clinical and regulatory outcomes that this data set does not contain. The 10-K itself reads as pure forward-looking optionality: every value driver — 'the timing or likelihood of regulatory filings and approvals,' 'the ability of our clinical trials to demonstrate the safety and efficacy of our product candidates,' 'the sufficiency of our existing cash to fund our future operating expenses' — is listed as an unresolved risk, not an achievement.

The numbers show a company sprinting toward a binary event, not one earning its way there. The net loss nearly doubled to -$300M (YoY -96.9%) and operating loss widened to -$315M, driven by R&D up 70.6% to $215M — the signature of a Phase 3 ramp. Operating cash burn hit -$241M against $355M of cash (itself raised via a financing that lifted cash +282.9% and diluted shares +16.1%). That leaves roughly 1.5 years of runway at the current pace, and burn is still accelerating, so another raise — more dilution — is a near-certainty before any approval generates a dollar of revenue.